Among these 3 trials, there was 1 case of breast cancer in the dutasteride group and 1 case in the placebo group.
Since tamsulosin is extensively metabolized, cautious dosage initiation at a lower dosage is prudent in patients with severe hepatic disease.
Simeprevir, a mild intestinal CYP3A4 inhibitor, may increase the side effects of tamsulosin, which is a CYP3A4 substrate.
Tamsulosin can cause orthostatic hypotension with accompanying dizziness or vertigo.
Use caution when administering ivacaftor and tamsulosin concurrently.